Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07587515
PHASE1/PHASE2

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Sponsor: Eyconis INC.

View on ClinicalTrials.gov

Summary

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Official title: Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-05-19

Completion Date

2028-05

Last Updated

2026-07-07

Healthy Volunteers

No

Interventions

BIOLOGICAL

EYC-0305

Extended-delivery anti-VEGF

Locations (6)

Beverly Hills, CA

Beverly Hills, California, United States

Wake Forest, NC

Wake Forest, North Carolina, United States

Erie, PA

Erie, Pennsylvania, United States

Bellaire, TX

Bellaire, Texas, United States

McAllen, TX

McAllen, Texas, United States

The Woodlands, TX

The Woodlands, Texas, United States